OJCD  Vol.4 No.1 , March 2014
Antimicrobial Resistance and Genotype Analysis of Extended-Spectrum-β-Lactamase-Producing Proteus Mirabilis
Abstract: To analyse the genotypes of clinical isolates of Extended-Spectrum-β-Lactamase-Producing (ESBL-producing) Proteus mirabilis (P. mirabilis) and the mechanisms of antimicrobial resistance, to guide reasonable use of antibiotics and to avoid nosocomial outbreak infections by ESBL-producing P. mirabilis. 125 clinical isolates of P. mirabilis were collected from the Drug-Resistant Bacteria Surveillance Center of Anhui Province (from Jan 2009 to May 2010). Searching for the genotypes of ESBLs was perfomed by PCR amplification and DNA sequencing, and performed conjugation test simultaneously. Among ESBL-producing strains, CTX-M was the major genotype (3 CTX-M-13 and 1 CTX-M-3). TEM-1b spectrum β-lactamase was also prevalence in P. mirabilis. The diversity of β-lactamases in P. mirabilis and the emergency of multi-drug-resistance clinical strains will present serious threat to clinical therapy and even will lead to outbreak of nosocomial infections. Our study emphasizes the need for enhanced supervision of ESBL-producing P. mirabilis. Timely and reasonable drug-resistance data are indispensable to clinical therapy.
Cite this paper: Huang, Y. , Xu, Y. , Wang, Z. and Lin, X. (2014) Antimicrobial Resistance and Genotype Analysis of Extended-Spectrum-β-Lactamase-Producing Proteus Mirabilis. Open Journal of Clinical Diagnostics, 4, 57-62. doi: 10.4236/ojcd.2014.41011.

[1]   O’Hara, C.M., Brenner, F.W. and Miller, J.M. (2000) Classification, Identification, and Clinical Significance of Proteus, Providencia, and Morganella. Clinical Microbiology Reviews, 13, 534-546.

[2]   Luzzaro, F., Mezzatesta, M., Mugnaioli, C., Perilli, M., Stefani, S., Amicosante, G., et al. (2006) Trends in Production of Extended-spectrum β-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. Journal of Clinical Microbiology, 44, 1659-1664.

[3]   Endimiani, A., Luzzaro, F., Brigante, G., Perilli, M., Lombardi, G., Amicosante, G., et al. (2005) Proteus Mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum β-Lactamases. Antimicrobial Agents and Chemotherapy, 49, 2598-2605.

[4]   Lewis, J.S., Herrera, M., Wickes, B., Patterson, J.E. and Jorgensen, J.H. (2007) First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System. Antimicrobial Agents and Chemotherapy, 51, 4015-4021.

[5]   Eckert, C., Gautier, V. and Arlet G. (2006) DNA Sequence Analysis of the Genetic Environment of Various blaCTX-M Genes. Journal of Antimicrobial Chemotherapy, 57, 14-23.

[6]   al Naiemi, N., Bart, A. and Jong, M.D., (2006) Widely Distributed and Predominant CTX-M Extended-Spectrum-β Lactamases in Amsterdam, The Netherlands. Journal of Clinical Microbiology, 44, 3012-3014.

[7]   Bonnet, R., De Champs, C., Sirot, D., Chanal, C., Labia, R. and Sirot, J. (1999) Diversity of TEM Mutants in Proteus Mirabilis. Antimicrobial Agents and Chemotherapy, 43, 2671-2677.

[8]   Song, W., Kim, J., Bae, I.K., Jeong, S.H., Seo, Y.H., Shin, J.H., et al. (2011) Chromosome-Encoded AmpC and CTX-M Extended-Spectrum β-Lactamases in Clinical Isolates of Proteus Mirabilis from Korea. Antimicrobial Agents and Chemotherapy, 55, 1414-1419.

[9]   Bradford, P.A. (2001) Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clinical Microbiology Reviews, 14, 933-951.

[10]   Luzzaro, F., Perilli, M., Amicosante, G., Lombardi, G., Belloni, R., Zollo, A., et al. (2001) Properties of Multidrug-Resistant, ESBL-Producing Proteus mirabilis Isolates and Possible Role of β-Lactam/β-Lactamase Inhibitor Combinations. International Journal of Antimicrobial Agents, 17, 131-135.

[11]   Pagani, L., Migliavacca, R., Pallecchi, L., Matti, C., Giacobone, E., Amicosante, G., et al. (2002) Emerging Extended-Spectrum-Lactamase in Proteus mirabilis. Journal of Clinical Microbiology, 40, 1549-1552.

[12]   Perilli, M., Dell’Amico, E., Segatore, B., de Massis, M.R., Bianchi, C., Luzzaro, F., Rossolini, G.M., et al. (2002) Molecular Characterization of Exetended-Spectrum-β-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey. Journal of Clinical Microbiology, 40, 611-614.

[13]   Arnoldo, L., Migliavacca, R., Regattin, L., Raglio, A., Pagani, L., Nucleo, E., et al. (2013) Prevalence of Urinary Colonization by Extended Spectrum-Beta-Lactamase Enterobacteriaceae among Catheterised Inpatients in Italian Long Term Care Facilities. BMC Infectious Diseases, 13, 124.

[14]   Marchandin, H., Jean-Pierre, H., De Champs, C., Sirot, D., Darbas, H., Perigault, P.F., et al. (2000) Production of a TEM-24 Plasmid-Mediated Extended-Spectrum-β-Lactamase by a Clinical Isolate of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 44, 213-216.

[15]   De Champs, C., Monne, C., Bonnet, R., Sougakoff, W., Sirot, D., Chanal, C., et al. (2001) New TEM Variant (TEM-92) Produced by Proteus mirabilis and Providencia Stuartii Isolates. Antimicrobial Agents and Chemotherapy, 45, 1278-1280.

[16]   Maurizio, S., Brunella, P., Teresa, S., et al. (2003) Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix ext Ended-Spectrum-lactamase Detection Method. Journal of Clinical Microbiology, 41, 1463-1468.

[17]   Bonnet, R., Samapaio, J.L., Labia, R., et al. (2000) A novel CTX-M β-Lactamases (CTX-M-8) in Cefotaxime-Resistant Enterobacteriaceae Isolated in Brazil. Antimicrobial Agents and Chemotherapy, 44, 1936-1942.

[18]   Saladin, M., Cao, V.T., Lambert, T., Donay, J.L., Herrmann, J.L., Ould-Hocine, Z., et al. (2002) Diversity of CTX-M-β-Lactamases and Their Promoter Regions from Enterobacteriaceae Isolated in Three Parisian Hospitals. FEMS Microbiology Letters, 209, 161-168.

[19]   Nagano, N., Shibata, N., Saitou, Y., Nagano, Y. and Arakawa, Y. (2003) Nosocomial Outbreak of Infections by Proteus mirabilis That Produces Extended-Spectrum CTX-M-2 Type β-Lactamase. Journal of Clinical Microbiology, 41, 5530-5536.

[20]   Ho, P.L., Ho, A.Y., Chow, K.H., Wong, R.C., Duan, R.S., Ho, W.L., et al. (2005) Occurrence and Molecular Analysis of Extended-Spectrum-β-Lactamase-Producing Proteus Mirabilis in Hong Kong, 1999-2002. Journal of Antimicrobial Chemotherapy, 55, 840-845.

[21]   Schwaber, M.J., Navon-Venezia, S., Kaye, K.S., Ben-Ami, R., Schwartz, D. and Carmeli, Y. (2006) Clinical and Economic Impact of Bacteremia with Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother, 50, 1257-1262.